DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02967757

Completed

In-market Utilisation of Liraglutide Used for Weight Management in Europe

In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study.

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

19

Recruiting sites

—

Enrollment

316

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoints

•BMI above or equal to 30 kg/m^2•BMI above or equal to 27kg/m^2 and below 30 kg/m^2 and 1 or more comorbidity•Above or equal to 27 kg/m^2 and below 30 kg/m^2 and no comorbidities

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02967757
Org study IDNN8022-4241
Secondary IDEUPAS16225EU PAS Register
Secondary IDU1111-1185-3661WHO

Timeline

Milestones

Study first posted2016-11-18estimated
Study start2016-12-22actual
Primary completion2019-05-28actual
Study completion2019-05-28actual
Last update posted2023-01-20actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

This is a descriptive study designed to examine in-market utilisation of liraglutide; thus there will be no hypothesis testing and a power calculation is not applicable. 100 patients will be enrolled for the pilot study (50 in each country, ) and additionally 300 patients will be enrolled for the full study (150 in each country)

Inclusion criteria

•Initiation of liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg (initiation is defined as no prescription of the same brand within the previous 12 months)
•Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability of the study

Exclusion criteria

-Patients or physicians who previously participated in interventional studies for liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg will not be eligible to participate in the study -For the full study, sites and patients included in the pilot will be excluded

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
4
Weight & body composition
2
Safety / tolerability / PK
2
Other clinical outcomes
2

Weight & body composition

2 endpoints
Primary/protocol endpoint

Number of patients with BMI above or equal to 30 kg/m^2

Time frame:Less than 6 months before date of first prescription

threshold achievement, improvement

Primary/protocol endpoint

Number of patients with BMI below 27 kg/m^2

Time frame:Less than 6 months before date of first prescription

threshold achievement, improvement

Safety / tolerability / PK

2 endpoints
Secondary/protocol endpoint

Number of patients with liraglutide 3.0 mg prescriptions who have reached a dose of 3.0 mg

Time frame:By 12 weeks after first prescription date

threshold achievement, descriptive

Secondary/protocol endpoint

Number of patients with continued treatment with liraglutide 3.0 mg

Time frame:From date of first prescription until 0-6 weeks; 7-12 weeks; 13-18 weeks; 19-24 months

descriptive

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Number of patients with BMI above or equal to 27kg/m^2 and below 30 kg/m^2 and 1 or more comorbidity

Time frame:Less than 6 months before date of first prescription

descriptive

Secondary/protocol endpoint

Number of patients with liraglutide 3.0 mg prescriptions and other GLP-1 receptor agonists prescribed during continued treatment with liraglutide 3.0 mg

Time frame:From date of first prescription until 24 months

descriptive

Other (unclassified)

4 endpoints
Primary/protocol endpoint/low confidence

Number of patients with above or equal to 27 kg/m^2 and below 30 kg/m^2 and no comorbidities

Time frame:Less than 6 months before date of first prescription

descriptive

Primary/protocol endpoint

Number of patients with BMI not measured

Time frame:Within 6 months before date of the first prescription

descriptive

Secondary/protocol endpoint

Number of patients with liraglutide 1.2 or 1.8 mg prescriptions with dose information of 3.0 mg per day

Time frame:From date of first prescription until 24 months

event count, descriptive

Secondary/protocol endpoint/low confidence

Number of patients with liraglutide 1.2 or 1.8 mg prescriptions and indication of weight management

Time frame:From date of first prescription until 24 months

event count, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.